■用于治疗帕金森病(PD)的多巴胺能药物的效果可以通过使用转换因子相互比较,以左旋多巴等效剂量(LED)计算。然而,目前关于MAO-B抑制剂(iMAO-B)沙司酰胺和雷沙吉兰的LED提案仍基于经验方法。
■估计50和100毫克的safinamide发光二极管。
■在这个多中心中,纵向,病例对照研究,我们回顾性回顾了500例连续PD患者的临床图表,这些患者患有运动并发症,并接受了(i)沙芬酰胺100mg(N=130),沙司酰胺50毫克(N=144),或雷沙吉兰1mg(N=97),持续9±3个月,对照组从未使用任何iMAO-B治疗(N=129)。
■主要基线特征(年龄,性别,疾病持续时间和阶段,运动体征和运动并发症的严重程度)在各组之间相似。雷沙吉兰患者的UPDRS-II评分和左旋多巴剂量低于对照组。经过8.8到10.1个月的平均随访,使用Safinamide50mg和100mg的患者的UPDRS-III和OFF相关UPDRS-IV评分低于对照组,与三个iMAO-B组相比,他们的总LED增加更大。在调整了年龄之后,疾病持续时间,随访时间,基线值,并考虑UPDRS-III评分的变化(敏感性分析),沙司酰胺100毫克相当于125毫克发光二极管,而沙芬酰胺50mg和雷沙吉兰1mg相当于100mgLED。
■我们使用了一种严格的方法来计算50和100mg沙芬酰胺的LED。需要大量前瞻性的务实试验来复制我们的发现。
UNASSIGNED: Effects of dopaminergic medications used to treat Parkinson\'s disease (PD) may be compared with each other by using conversion factors, calculated as Levodopa equivalent dose (
LED). However, current
LED proposals on MAO-B inhibitors (iMAO-B) safinamide and rasagiline are still based on empirical approaches.
UNASSIGNED: To estimate
LED of safinamide 50 and 100 mg.
UNASSIGNED: In this multicenter, longitudinal,
case-control study, we retrospectively reviewed clinical charts of 500 consecutive PD patients with motor complications and treated with (i) safinamide 100 mg (N = 130), safinamide 50 mg (N = 144), or rasagiline 1 mg (N = 97) for 9 ± 3 months and a control group of patients never treated with any iMAO-B (N = 129).
UNASSIGNED: Major baseline features (age, sex, disease duration and stage, severity of motor signs and motor complications) were similar among the groups. Patients on rasagiline had lower UPDRS-II scores and Levodopa dose than control subjects. After a mean follow-up of 8.8-to-10.1 months, patients on Safinamide 50 mg and 100 mg had lower UPDRS-III and OFF-related UPDRS-IV scores than control subjects, who in turn had larger increase in total LED than the three iMAO-B groups. After adjusting for age, disease duration, duration of follow-up, baseline values and taking change in UPDRS-III scores into account (sensitivity analysis), safinamide 100 mg corresponded to 125 mg LED, whereas safinamide 50 mg and rasagiline 1 mg equally corresponded to 100 mg
LED.
UNASSIGNED: We used a rigorous approach to calculate LED of safinamide 50 and 100 mg. Large prospective pragmatic trials are needed to replicate our findings.